The IsletTester Mouse: An Immunodeficient Model With Stable Hyperglycemia for the Study of Human Islets
Current mouse models for assessing islet function in vivo are limited due to unstable and variable hyperglycemia and/or high morbidity. We derived the IsletTester mouse to address these limitations. Leveraging a previously characterized glucokinase mutation and CRISPR/Cas9 technology, we successfully developed a moderately hyperglycemic and immunodeficient mouse model for the in vivo assessment of islet function. Our IsletTester mouse has stable, moderate hyperglycemia that can be corrected with primary human islets or stem cell-derived insulin-producing cells. The IsletTester mouse provides a reliable, easy-to-use platform for the preclinical assessment of stem cell-derived islet products or islet-targeted drugs.
Authors
- Klaus H. Kaestner (ORCID: https://orcid.org/0000-0002-1228-021X)
- Dana Avrahami
- Nicolai M. Doliba (ORCID: https://orcid.org/0000-0003-4598-9222)
- Kathleen Kelly (ORCID: https://orcid.org/0000-0002-5631-2121)
- Mark Tigue
- Kim-Vy Nguyen-Ngoc
- Eric L. Waite (ORCID: https://orcid.org/0000-0003-3023-3641)
- Catherine Lee May
- Benjamin Gläser (ORCID: https://orcid.org/0000-0003-4711-5000)
- Ali Naji (ORCID: https://orcid.org/0000-0002-6926-3306)
- Ming Yu (ORCID: https://orcid.org/0000-0003-4264-5811)
- Deeksha Lahori
- Maike Sander
- Jeffrey Roman
Institutions
- Hebrew University of Jerusalem (IL)
- Max Delbrück Center (DE)
- Hospital of the University of Pennsylvania (US)
- Hadassah Medical Center (IL)
- University of California San Diego (US)
- Concern Foundation (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Diabetes
- Published
- 2024-11-21
- DOI
- https://doi.org/10.2337/db23-0887
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 1.15